Infante-Sierra H, Crespo-Solís E, López KX, Serralde A, López-de la Cruz I, Aguayo A

Idioma: Español
Referencias bibliográficas: 38
Paginas: 150-155
Archivo PDF: 110.75 Kb.

FRAGMENTO

Introducción

La leucemia mieloide aguda (LMA) comprende un grupo heterogéneo de enfermedades con diferente pronóstico. Con la quimioterapia actual la remisión hematológica se consigue en 50-80% de los pacientes con reciente diagnóstico de LMA; sin embargo, a pesar del tratamiento de consolidación la mayoría de los pacientes recae.
Algunos factores al momento del diagnóstico, tales como la edad, estado físico, cuenta leucocitaria y el cariotipo son relevantes para el pronóstico y evolución; siendo la citogenética convencional el factor más importante relacionado con la remisión completa (RC), supervivencia global (SG) y supervivencia libre de enfermedad (SLE). El pronóstico de los pacientes con LMA después de la primera recaída es por lo general pobre.

REFERENCIAS (EN ESTE ARTÍCULO)

1. McCulloch EA, Kellecher CA, Miyauchi J, Wang C, Chan GY, Minden MD et al. Heterogeneity in acute myeloblastic leukemia. Leukemia 1998; 2(12 Suppl): 38s-49s.

2. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331(14): 896-903.

3. Appelbaum FR, Kopecky KJ. Long-term survival after chemotherapy for acute myeloid leukemia: the experience of the Southwest Oncology Group. Cancer 1997; 80: 2199-2204.

4. Burnett AK, Glodstone AH, Stevens RM, Hann IM, Ress JK, Gray RG, Wheatley K. Randomized comparison of addition of autologous bone marrow transplantation to intensive chemotherapy for acute myeloid leukemia in first remission: results of MC AML 10 trial. Lancet 1998; 351(9104): 700-708.

5. Löwenberg B, Downing JR, Burnett A. Acute Myeloid Leukemia. N Engl J Med 1999; 341(14): 1051-1062.

6. Berger R, Flandrin G, Bernheim A, Le Coniat M, Vecchione D, Pacot A et al. Cytogenetic studies on 519 consecutive de novo acute nonlymphocytic leukemias. Cancer Genet Cytogenet 1987; 29(1): 9-21.

7. Keating MJ, Smith TL, Kantarjian H, Cork A, Walters R, Trujillo JM et al. Cytogenetic pattern in acute myeloid leukemia: a major reproducible determinant of outcome. Leukemia 1988; 2(7): 403-412.

8. Dastugue N, Payen C, Lafage-Pochitaloff M, Bernard P, Leroux D, Huget-Rigal F et al. Prognostic significance of Karyotype in the novo adult acute myeloid leukemia. Leukemia 1995; 9(9): 1491-1498.

9. Kern W, Schoch C, Haferlach T, Braess J, Unterhalt M, Wormann B et al. Multivariate analysis of prognosis factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. Leukemia 2000; 14(2): 226-231.

10. Weltermann A, Fonastsch C, Hass OA, Greinix HT, Kahls P, Mitterbauer G et al. Impact of cytogenetics on the prognosis of adults with de novo AML in first relapse. Leukemia 2004; 18(2): 293-302.

11. Stoiser B, Knobl P, Fonatsch C, Initterbauer G, Welterman A, Geissler K et al. Prognosis of patients with a second relapse of acute myeloid leukemia. Leukemia 2000; 14(12): 2059-2063.

12. Tavernier E, Le QH, Elhamri M, Thomas X. Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors. Leuk Res 2003; 27(3): 205-214.

13. Estey E. Reducing mortality associated with immediate treatment complications of adult leukemias. Semin Hematol 2001; 38(4 Suppl 10): 32-37.

14. Bloomfield C, Shuma C, Regal L, Philip PP, Hossfeld DK, Hagemeijer AM et al. Long-term survival in patients with acute myeloid leukaemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer 1997; 80(11 Suppl): 2191-2198.

15. Wilhelm M, Kantarjian HM, O´Bren S, Pierce S, Keating MJ, Freireich EJ et al. Pneumonia during remission induction chemotherapy in patients with AML or MDS. Leukemia 1996; 10 (12): 1870-1873.

16. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: Emphasis on Gram-positive and resistant bacteria. Clin Infect Dis 1999; 29(3): 490-494.

17. Slats AM, Egeler RM, Van der Does-Van der Ber A, Korbijin C, Hahlen K, Kamps WA et al. Causes of death -other than progressive leukemia- in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): The Dutch childhood oncology group experience. Leukemia 2005; 19(4): 537-544.

18. Anderlini P, Luna M, Kantarjian HM, O´Brien S, Prerce S, Keating MJ et al. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes. Leukemia 1996; 10(4): 600-608.

19. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Granlnick HR et al. Criteria for the diagnosis of acute leukaemia of megakaryocytic lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103(3): 460-462.

20. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Granlnick HR et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Br J Haematol 1991; 78(3): 325-329.

21. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Granlnick HR et al. Hypergranular promyelocytic leukemia: correlation between morphology and chromosomal translocations including t(15;17) and t(11;17). Leukemia 2000; 14(7): 1997-2000.

22. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukemia Working Parties. Blood 1998; 92(7): 2322-33.

23. Cheson BD, Cassileth PA, Head DR, Schiffer GA, Bennett JM, Bloomfield CD et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute leukemia. J Clin Oncol 1990; 8(5): 813-819.

24. Sandler DP, Ross JA. Epidemiology of acute leukemia in children and adults. Semin Oncol 1997; 24(1): 3-16.

25. Sekeres MA, Stone RM, Zahrieh D, Neuberg D, Morrison V, De Angelo DJ et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2004; 18(14):809-16.

26. Piedras J, López Karpovitch X, Cárdenas MR. Inmunofenotipos celulares en 97 adultos con leucemia aguda. Rev Invest Clin 1997; 49 (6): 457-464.

27. Bullinger L, Valk PJ. Gene expression profiling in acute myeloid leukaemia. J Clin Oncol 2005; 23(26): 6296-6305.

28. Orfao A, Schmitz B, Brando B, Ruíz-Argüelles A, Basso G, Braylan R et al. Clinically Useful Information Provided by the Cytometric Immunophenotyping of hematological malignancies: Current status and future directions. Clin Chem 1999; 45(10): 1708-1717.

29. Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukaemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1,091 patients with de novo AML. Leukemia 2004; 18 (1): 120-125.

30. Crespo E, López Karpovitch X, Abraham-Simon J, Lome-Maldonado C, Piedras J. Supervivencia, características clínicas y de laboratorio en leucemias megacarioblásticas de novo y secundaria. Rev Invest Clin 2003; 55(5): 494-501.

31. Juliusson G, Billstrom R, Gruber A, Hellström-Lindberg E, Hoglunds M, Karlsson K et al. Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival. Leukemia 2006; 20(1): 42-47.

32. Estey E. Prognostic factors in acute myelogenous leukemia. Leukemia 2001; 15(4): 670-2.

33. Yates JW, Wallace HJ Jr, Ellison RR. Cytosine arabinose and daunorubicin therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep 1973; 52(4): 485.

34. Herzig R, Lazarus HM, Wolff SN, Phillips GL, Herzig GD. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute non-lymphoblastic leukaemia. J Clin Oncol 1985; 3(7): 992-997.

35. Estey EH. Therapeutic options for acute myelogenous leukemia. Cancer 2001; 92(5): 1059-73.

36. Cassileth PA, Begg CB, Bennett JM, Bozdech M, Kahn SB, Weiter C et al. A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukaemia. Blood 1984; 63(4): 843-847.

37. Yates JW, Wallace HJ Jr, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukaemia. Cancer Treat Rep 1973; 57(4): 485-488.

38. Levi I, Grotto I, Yerushalmi R, Ben-Bassat I, Sphpilberg O. Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission. Leukemia Research 2004; 28(6): 605-612.